Cost Effectiveness of Tumour Necrosis Factor-α Inhibitors as First-Line Agents in Rheumatoid Arthritis

By Spalding James R.  

PharmacoEconomics, Vol. 24, Iss. 12, 2006-01 ,pp. : 1221-1232

Adis International

Access to resources Recommend Favorite

Cost Utility of Tumour Necrosis Factor-α Inhibitors for Rheumatoid Arthritis: An Application of Bayesian Methods for Evidence Synthesis in a Markov Model

By Nguyen Christine M.   Bounthavong Mark   Mendes Margaret A.S.   Christopher Melissa L.D.   Tran Josephine N.   Kazerooni Rashid   Morreale Anthony P.  

PharmacoEconomics, Vol. 30, Iss. 7, 2012-07 ,pp. : 575-593

Adis International

Access to resources Recommend Favorite

Tumour necrosis factor-α inhibitors/immunosuppressants: Cancer: 3 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1423, 2012-01 ,pp. : 48-48

Adis International

Access to resources Recommend Favorite

Local versus Systemic Anti-Tumour Necrosis Factor-α Effects of Adalimumab in Rheumatoid Arthritis: Pharmacokinetic Modelling Analysis of Interaction between a Soluble Target and a Drug

By Stepensky David  

Clinical Pharmacokinetics, Vol. 51, Iss. 7, 2012-07 ,pp. : 443-455

Adis International

Access to resources Recommend Favorite

Tumour Necrosis Factor-α Antagonists in the Management of Rheumatoid Arthritis in the Elderly: A Review of Their Efficacy and Safety

By Radovits Beáta J.   Kievit Wietske   Laan Roland F.J.M.  

Drugs & Aging, Vol. 26, Iss. 8, 2009-08 ,pp. : 647-664

Adis International

Access to resources Recommend Favorite